China's self-developed novel tuberculosis mRNA vaccine has begun clinical trials at Beijing Chest Hospital, as reported by the Beijing Evening News.
Animal studies have demonstrated that the protective efficacy of this new vaccine is over 20 times greater than that of Bacillus Calmette-Guerin (BCG) and other foreign tuberculosis vaccines. This vaccine, which holds independent intellectual property rights, aims to provide a new vaccination option for individuals of all ages and effectively reduce the incidence and infection rates of tuberculosis.
The research and development team will further investigate various aspects of the vaccine, including immunization strategies, immune responses, administration routes, and adaptation symptoms, according to Pang Yu, head of the hospital's bacteriological immunology department.
In addition, the hospital has launched an AI diagnosis model and a rapid detection method for tubercle bacillus bacteria using tongue swabs. This diagnosis model enables remote, non-invasive early detection of pulmonary diseases, including tuberculosis. It is currently in the preclinical stage, while the rapid detection method is expected to be gradually implemented nationwide starting in July.
(Source: Xinhua)
Related News:
Toddler and paediatric formulation of JN.1 COVID-19 vaccines to be provided end of month
Flu epidemic claims lives: HK sees 20% increase in vaccinations
Comment